Channel Medical Partners

Stuart K. Ennis and Christopher J. Addonizio, who co-founded the firm in 2002, serve as Managing Directors and make all investment decisions jointly. Both came from investment banking backgrounds — Ennis from Lehman Brothers and Addonizio from Wasserstein Perella — before focusing their careers on medical device investing. The firm operates without a large investment committee, giving the two partners full discretion over portfolio construction and exit timing.

Channel targets commercial-stage medical device companies that have already secured FDA clearance or a CE mark and are generating revenue. The firm typically invests in companies with $5 million to $20 million in annual revenue. This sits between early venture capital and large-scale buyout territory — companies too large for seed-stage medtech VCs but too small and clinically specialized for generalist growth equity or mega-funds.

No. Channel explicitly focuses on companies with regulatory-cleared products and existing commercial revenue. The firm does not invest in pre-clinical, IDE-stage, or pre-revenue medical device startups. This later-stage approach means the binary regulatory risk has already been resolved before Channel commits capital.

Channel invests broadly across medical device subsectors including cardiovascular, orthopedics, surgical instrumentation, diagnostics, and neuromodulation. The firm has backed companies like CardioMEMS (heart failure monitoring, acquired by St. Jude Medical), Rhythmia Medical (electrophysiology mapping, acquired by Boston Scientific), and Intersect ENT (sinus implants, acquired by Medtronic). The firm avoids biotech, pharmaceuticals, and digital health platforms, maintaining a pure hardware and instrumentation focus.

Channel operates as a traditional private equity partnership with institutional limited partners including endowments, foundations, and fund-of-funds. The firm is not a single-family office, a corporate venture arm, or an incubator. It raises blind-pool funds — most recently Channel Medical Partners III in 2022 — and charges standard management fees and carried interest. The firm runs a lean operation with most investment and operational functions handled by the two founding partners and a small support team.

Channel holds investments for approximately 5 to 7 years, which is longer than the typical medtech venture holding period of 3 to 5 years. The firm's exit strategy relies almost exclusively on strategic acquisition by larger medical device companies. Channel does not typically pursue IPOs as a primary exit path, given the acquisition appetite of major strategics like Medtronic, Boston Scientific, and St. Jude Medical (now part of Abbott) for the sub-$500 million revenue targets Channel cultivates.

Channel invests primarily in the United States and Western Europe, where the regulatory pathways (FDA and CE mark) are well-defined and the strategic acquirers are concentrated. The firm sources opportunities across both regions and has historically maintained a US-heavy portfolio. Channel does not invest in emerging-market medical device companies where regulatory enforcement and exit markets are less predictable.